132 related articles for article (PubMed ID: 3871772)
1. A synthetic nonapeptide corresponding to the NH2-terminal sequence of C3d-K causes leukocytosis in rabbits.
Hoeprich PD; Dahinden CA; Lachmann PJ; Davis AE; Hugli TE
J Biol Chem; 1985 Mar; 260(5):2597-600. PubMed ID: 3871772
[TBL] [Abstract][Full Text] [Related]
2. Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.
Meuth JL; Morgan EL; DiSipio RG; Hugli TE
J Immunol; 1983 Jun; 130(6):2605-11. PubMed ID: 6602172
[TBL] [Abstract][Full Text] [Related]
3. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
4. The active site of human C4a anaphylatoxin.
Hugli TE; Kawahara MS; Unson CG; Molinar-Rode R; Erickson BW
Mol Immunol; 1983 Jun; 20(6):637-45. PubMed ID: 6603573
[TBL] [Abstract][Full Text] [Related]
5. Bioactive complement fragments in immunoregulation.
Morgan EL; Thoman ML; Hoeprich PD; Hugli TE
Immunol Lett; 1985; 9(4):207-13. PubMed ID: 3873407
[TBL] [Abstract][Full Text] [Related]
6. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides.
Lambris JD; Avila D; Becherer JD; Müller-Eberhard HJ
J Biol Chem; 1988 Aug; 263(24):12147-50. PubMed ID: 2969896
[TBL] [Abstract][Full Text] [Related]
7. Limited proteolysis of a chemically modified third component of human complement, C3, by cathepsin G of human leukocytes.
Matsuda T; Nagasawa S; Koide T; Koyama J
J Biochem; 1985 Jul; 98(1):229-36. PubMed ID: 4044552
[TBL] [Abstract][Full Text] [Related]
8. Absence of induction of IL-1 production in human monocytes by complement fragments.
Arend WP; Massoni RJ; Niemann MA; Giclas PC
J Immunol; 1989 Jan; 142(1):173-8. PubMed ID: 2783323
[TBL] [Abstract][Full Text] [Related]
9. Limited proteolysis of complement protein C3b by regulatory enzyme C3b inactivator: isolation and characterization of a biologically active fragment, C3d,g.
Seya T; Nagasawa S
J Biochem; 1985 Jan; 97(1):373-82. PubMed ID: 3158646
[TBL] [Abstract][Full Text] [Related]
10. Generation of the bioactive kallikrein-derived fragment, C3d-k, by HANE-plasma.
Seya T; Nagasawa S; Atkinson JP
Clin Exp Immunol; 1985 Oct; 62(1):208-16. PubMed ID: 3851703
[TBL] [Abstract][Full Text] [Related]
11. Human C5a des Arg increases vascular permeability.
José PJ; Forrest MJ; Williams TJ
J Immunol; 1981 Dec; 127(6):2376-80. PubMed ID: 6170701
[TBL] [Abstract][Full Text] [Related]
12. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.
Lambris JD; Ganu VS; Hirani S; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4235-9. PubMed ID: 2408276
[TBL] [Abstract][Full Text] [Related]
13. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized.
Ganu VS; Müller-Eberhard HJ; Hugli TE
Mol Immunol; 1989 Oct; 26(10):939-48. PubMed ID: 2531841
[TBL] [Abstract][Full Text] [Related]
14. Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.
Gerard C; Hugli TE
Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1833-7. PubMed ID: 6940191
[TBL] [Abstract][Full Text] [Related]
15. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin.
Hugli TE; Erickson BW
Proc Natl Acad Sci U S A; 1977 May; 74(5):1826-30. PubMed ID: 266705
[TBL] [Abstract][Full Text] [Related]
16. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism.
Rodriguez E; Nan R; Li K; Gor J; Perkins SJ
J Biol Chem; 2015 Jan; 290(4):2334-50. PubMed ID: 25488663
[TBL] [Abstract][Full Text] [Related]
17. The active site of C3a anaphylatoxin.
Caporale LH; Tippett PS; Erickson BW; Hugli TE
J Biol Chem; 1980 Nov; 255(22):10758-63. PubMed ID: 6968751
[TBL] [Abstract][Full Text] [Related]
18. Structure and function of the anaphylatoxins.
Hugli TE
Springer Semin Immunopathol; 1984; 7(2-3):193-219. PubMed ID: 6387982
[TBL] [Abstract][Full Text] [Related]
19. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.
Fernandez HN; Hugli TE
J Biol Chem; 1978 Oct; 253(19):6955-64. PubMed ID: 690134
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of interleukin 3 function by a fragment of the third component of complement.
Fassbender B; Schmitt E; Bitter-Suermann D; Hadding U
Eur J Immunol; 1987 May; 17(5):695-700. PubMed ID: 3495444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
